Breast cancer and triple-negative breast cancer
Research activity is concentrated in breast cancer, with strong emphasis on triple-negative breast cancer (TNBC) across early-stage, high-risk, locally advanced, and metastatic settings. The portfolio also includes HER2-positive disease, ER-positive, HER2-negative metastatic disease, and molecularly defined subgroups such as GATA3-mutant and HER3-mutant breast cancer.
- Early and metastatic triple-negative breast cancer
- HER2-positive metastatic breast cancer
- ER-positive, HER2-negative metastatic breast cancer
- Molecularly selected breast cancer subtypes
Interest extends to recurrence detection, biomarker-guided treatment selection, and post-treatment monitoring in advanced breast malignancies.
Ocular oncology and retinoblastoma
The sponsor funds clinical research in retinoblastoma, with a focus on conservative management, ocular preservation, and visual outcome. Studies address unilateral and bilateral disease, including cases with vitreous seeding and eyes requiring local control strategies.
- Retinoblastoma
- Ocular preservation
- Local ophthalmologic treatments
- Visual function outcomes
Additional interest includes treatment approaches after primary enucleation and strategies that reduce reliance on external beam radiation.
Melanoma and rare solid tumours
Clinical research also covers metastatic uveal melanoma and broader recurrent or metastatic solid cancer, reflecting interest in advanced disease settings where therapeutic options remain limited.
- Metastatic uveal melanoma
- Recurrent and metastatic solid tumours
- Advanced cancer with molecular alterations
The portfolio includes work in biomarker-defined advanced cancers and immunotherapy-based approaches in difficult-to-treat malignancies.
Central nervous system and pancreatic cancer
Institut Curie supports studies in primary central nervous system lymphoma (PCNSL) and non-metastatic pancreatic ductal adenocarcinoma, extending its oncology activity beyond breast and eye cancers into aggressive solid and hematologic malignancies.
- Primary central nervous system lymphoma
- Pancreatic ductal adenocarcinoma
- Advanced lymphoma and solid tumour care
These areas include interest in disease control, treatment response, and molecularly informed therapeutic development.
Imaging biomarkers, ctDNA, and supportive care
Several trials focus on molecular imaging and circulating biomarkers, particularly FAPI PET/CT and ctDNA surveillance, alongside research in perioperative care for breast surgery.
- FAPI PET/CT imaging biomarkers
- Circulating tumour DNA surveillance
- Perioperative anaesthesia in breast reconstruction
These activities connect diagnosis, risk assessment, and treatment monitoring across oncology care pathways.
